Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Peanut Allergy
- Main trialPhase 1
- “This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.”In the company’s words, NCT05476497 on ClinicalTrials.gov
Other drugs for Peanut Allergy
- Viaskin PeanutDBV Technologies · Phase 3
- RemibrutinibNovartis · Phase 3
- UKK-0018Ukko Inc · Phase 1/2
- RPT904RAPT Therapeutics, Inc., a member of the GSK plc group of companies · Phase 2
- ENP-501N-Fold, LLC · Phase 1/2
- LP-003Longbio Pharma · Phase 2
Coming up1
- NovPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Nov 2026 | Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026